Evolution News and Research

RSS

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

Baby's sleep position can predict misshapen skull condition

A baby's sleep position is the best predictor of a misshapen skull condition known as deformational plagiocephaly - or the development of flat spots on an infant's head - according to findings reported by Arizona State University scientists in the December issue of the journal Pediatrics.

18 Nov 2009

In home evaluation trials for GeckoSystems' home care robot begins

GeckoSystems Intl. Corp. (http://www.geckosystems.com/) announced today that they have started limited in home evaluation trials for their first product, a fully autonomous personal companion home care robot, the CareBot™.

18 Nov 2009

NCQA to revise landmark evaluation of medical practices to improve care quality

The National Committee for Quality Assurance (NCQA) today announced plans to revise its landmark evaluation of medical practices through the Physician Practice Connections®-Patient-Centered Medical Home™ (PPC®-PCMH™) to reflect the growing interest in this promising approach to improving care quality.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

Reducing payments fraud is top priority for issuers and acquirers to adopt EMV/chip in Brazil and Mexico

Cartes & Identification -- Reducing payments fraud is the top driver for issuers and acquirers to adopt EMV/chip in Brazil and Mexico, according to a new study from the Smart Card Alliance Latin America (SCALA), produced in participation with Visa Inc., available for sale today.

17 Nov 2009

Researchers attempt to slow the pace of infectious organisms' evolution to keep today's drugs effective

Infectious organisms that become resistant to antibiotics are a serious threat to human society. They are also a natural part of evolution. In a new project, researchers at the University of Gothenburg are attempting to find substances that can slow the pace of evolution, in order to ensure that the drugs of today remain effective into the future.

17 Nov 2009

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

16 Nov 2009

Some combination drug therapies are counter-productive

Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

16 Nov 2009

GeckoSystems starts in home evaluation trials for CareBot

GeckoSystems Intl. Corp. (http://www.geckosystems.com/) announced today that they are starting limited in home evaluation trials for their first product, a personal companion home care robot, the CareBot™.

16 Nov 2009

Changes in CMS reimbursement to accelerate demand for cardiac PET imaging

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.

13 Nov 2009

NJIT's EDC companies receive $1.4M funding from the New Jersey Commission on Science and Technology

A drug to stop bleeding during a brain injury and a mattress that will prevent bedsores are among the scientific discoveries at NJIT that received earlier this week more than a million dollars in funding from the New Jersey Commission on Science and Technology. The discoveries are the work of five early stage companies based at NJIT's Enterprise Development Center (EDC), the state's oldest business incubator program.

13 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). The research, published by Cell Press in the November 12 issue of the journal Neuron, finds that the novel gene interacts with a key cellular enzyme previously linked with AD pathology, thereby uncovering a new strategy for treating this devastating disorder.

12 Nov 2009

UK research funders announce support for a series of H1N1 2009 research projects

Leading UK research funders today announce -7.5 million of funding for a series of projects aimed at understanding the development and spread of pandemic influenza H1N1 2009 - or 'swine flu'. The research will look at every aspect of the virus, on pig farms, in pig and human populations, and in hospital intensive care units.

11 Nov 2009

Hand washing: Best method for killing germs and protecting oneself from flu

Fears of contracting the H1N1 virus this flu season have people steering clear of strangers with coughs and scolding friends who don't sneeze into their crooked elbows. With everyone trying to stay germ free, hand sanitizer has become a popular means of protection. But although a quick pump from a Purell dispenser is the most convenient form of hand cleaning, is it the best?

11 Nov 2009

An interpretive guide to the origin of species

World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009